Nassri Ammar, Ramzan Zeeshan
Ammar Nassri, Department of Internal Medicine, University of Texas at Austin Dell Medical School, Austin, TX 78701, United States.
World J Gastrointest Pharmacol Ther. 2015 Nov 6;6(4):145-55. doi: 10.4292/wjgpt.v6.i4.145.
This article reviews currently available pharmacological options available for the treatment of achalasia, with a special focus on the role of botulinum toxin (BT) injection due to its superior therapeutic effect and side effect profile. The discussion on BT includes the role of different BT serotypes, better pharmacological formulations, improved BT injection techniques, the use of sprouting inhibitors, designer recombinant BT formulations and alternative substances used in endoscopic injections. The large body of ongoing research into achalasia and BT may provide a stronger role for BT injection as a form of minimally invasive, cost effective and efficacious form of therapy for patients with achalasia. The article also explores current issues and future research avenues that may prove beneficial in improving the efficacy of pharmacological treatment approaches in patients with achalasia.
本文综述了目前可用于治疗贲门失弛缓症的药物选择，特别关注肉毒杆菌毒素（BT）注射的作用，因为其具有卓越的治疗效果和副作用特征。关于BT的讨论包括不同BT血清型的作用、更好的药物制剂、改进的BT注射技术、发芽抑制剂的使用、定制重组BT制剂以及内镜注射中使用的替代物质。目前对贲门失弛缓症和BT的大量研究可能会使BT注射作为一种微创、经济有效且高效的治疗方式在贲门失弛缓症患者中发挥更重要的作用。本文还探讨了当前的问题以及未来的研究途径，这些可能有助于提高贲门失弛缓症患者药物治疗方法的疗效。
